Alzheimer Disease: Postmortem Neuropathologic Correlates of Antemortem1H MR Spectroscopy Metabolite Measurements1
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
PURPOSE: To determine the neuropathologic correlates of antemortem hydrogen 1 ((1)H) magnetic resonance (MR) spectroscopy metabolite measurements in subjects with Alzheimer disease (AD)-type pathology. MATERIALS AND METHODS: This study was approved by the institutional review board and was compliant with HIPAA regulations. Informed consent was obtained from each subject. The authors identified 54 subjects who underwent antemortem (1)H MR spectroscopy and were clinically healthy or had AD-type pathology with low to high likelihood of AD according to National Institute on Aging-Reagan neuropathologic criteria at autopsy. They investigated the associations between (1)H MR spectroscopy metabolite measurements and Braak neurofibrillary tangle stage (Braak stage), neuritic plaque score, and AD likelihood, with adjustments for subject age, subject sex, and time between (1)H MR spectroscopy and death. RESULTS: Decreases in N-acetylaspartate-to-creatine ratio, an index of neuronal integrity, and increases in myo-inositol-to-creatine ratio were associated with higher Braak stage, higher neuritic plaque score, and greater likelihood of AD. The N-acetylaspartate-to-myo-inositol ratio proved to be the strongest predictor of the pathologic likelihood of AD. The strongest association observed was that between N-acetylaspartate-to-myo-inositol ratio and Braak stage (R(N)(2) = 0.47, P < .001). CONCLUSION: Antemortem (1)H MR spectroscopy metabolite changes correlated with AD-type pathology seen at autopsy. The study findings validated (1)H MR spectroscopy metabolite measurements against the neuropathologic criteria for AD, and when combined with prior longitudinal (1)H MR spectroscopy findings, indicate that these measurements could be used as biomarkers for disease progression in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992 · cited 1×
“However, given the complexity of the abnormalities that underlie dementia in elderly individuals (eg, AD-type, cerebrovascular, and Lewy body pathologies), it is clear why a single imaging marker is not sufficient for the early diagnosis of dementia (60, 61).”
BackgroundHYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Jack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958
Self-citationDeKosky, S. T., Ikonomovic, M. D., Styren, S. D., Beckett, L., Wisniewski, S., Bennett, D. A., Cochran, E. J., Kordower, J. H., & Mufson, E. J. (2002) · Annals of Neurology · doi:10.1002/ana.10069 · Cited by 686 · cited 2×
“The fact that we identified no associations between Cho/Cr ratio and indexes of AD-type pathology suggests that the cross-sectional or longitudinal Cho/Cr changes observed with amnestic MCI and AD may be related to functional mechanisms that are independent of the neurofibrillary abnormality, such as alterations in ch…”
BackgroundAntemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia
Jack, C. R., Dickson, D. W., Parisi, J. E., Xu, Y. C., Cha, R. H., O’Brien, P. C., Edland, S. D., Smith, G. E., Boeve, B. F., Tangalos, E. G., et al. (2002) · Neurology · doi:10.1212/wnl.58.5.750 · Cited by 610 · cited 1×
“Combining the information gleaned from different quantitative MR examinations such as volumetric MR imaging, (1)H MR spectroscopy, and diffusion MR imaging or other imaging modalities such as (18)F fluorodeoxyglucose PET and amyloid ligand PET may further improve the diagnostic value of imaging for the early diagnosis…”
MethodSelf-citationAlzheimer Disease With Amygdala Lewy Bodies: A Distinct Form of α-Synucleinopathy
Uchikado, H., Lin, W.-L., DeLucia, M. W., & Dickson, D. W. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000225908.90052.07 · Cited by 359
Self-citationModrego, P. J., Fayed, N., & Pina, M. A. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.4.667 · Cited by 135
Quantitative magnetic resonance techniques as surrogate markers of Alzheimer’s disease
Kantarci, K., & Jack, C. R. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.196 · Cited by 80
Self-citation
Cited by
The clinical use of structural MRI in Alzheimer disease
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.215 · Cited by 2,113
Self-citationClinical Proton MR Spectroscopy in Central Nervous System Disorders
Öz, G., Alger, J. R., Barker, P. B., Bartha, R., Bizzi, A., Boesch, C., Bolan, P. J., Brindle, K. M., Cudalbu, C., Dinçer, A., et al. (2014) · Radiology · doi:10.1148/radiol.13130531 · Cited by 660
Self-citationSong, T., Song, X., Zhu, C., Patrick, R., Skurla, M., Santangelo, I., Green, M., Harper, D., Ren, B., Forester, B. P., et al. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101503 · Cited by 346
Brain Glutamate Levels Are Decreased in Alzheimer’s Disease: A Magnetic Resonance Spectroscopy Study
Fayed, N., Modrego, P. J., Rojas-Salinas, G., & Aguilar, K. (2011) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317511421780 · Cited by 128
Magnetic Resonance Spectroscopy in Alzheimer’s Disease: Systematic Review and Meta-Analysis
Wang, H., Tan, L., Wang, H.-F., Liu, Y., Yin, R.-H., Wang, W.-Y., Chang, X.-L., Jiang, T., & Yu, J.-T. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-143225 · Cited by 123
Metadata
- Authors
- Kantarci, K., Knopman, D. S., Dickson, D. W., Parisi, J. E., Whitwell, J. L., Weigand, S. D., Josephs, K. A., Boeve, B. F., Petersen, R. C., & Jack, C. R.
- Venue
- Radiology
- Published
- 2008-07
- Volume
- 248
- Issue
- 1
- Pages
- 210-220
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2105182553
- Cited by
- 163
- References
- 12
- FWCI
- 8.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.